Elanco Animal Health, Inc. develops, manufactures, and markets products for pets and farm animals. The company is headquartered in Indianapolis, Indiana and currently employs 9,400 full-time employees. The company went IPO on 2018-09-20. The firm is engaged in delivering products and services to prevent and treat disease in farm animals and pets. The company serves animals across species, including dogs, cats, cattle, poultry, swine and sheep. Its pet health products help pets live longer, healthier and more active lives. Its pet health portfolio is focused on parasiticides, dermatology, vaccines and pain/other therapeutics. The company includes parasiticide portfolios in the pet health market based on indications, species and formulations, with products that protect pets from fleas, ticks and internal parasites. The company offers Advantage, K-9 Advantix, Advocate, and AdTab, which are over-the-counter treatments for the prevention and elimination of fleas and ticks. Its farm animal products help producers improve animal health and wellbeing. The company offers a farm animal portfolio of products for cattle including beef and dairy, poultry, swine and sheep.
What is Elanco Animal Health Inc (ELAN)'s P/E Ratio?
The P/E ratio of Elanco Animal Health Inc is 35.8683
Who is the CEO of Elanco Animal Health Inc?
Mr. Jeffrey Simmons is the President of Elanco Animal Health Inc, joining the firm since 2018.
What is the price performance of ELAN stock?
The current price of ELAN is $25.04, it has increased 5.96% in the last trading day.
What are the primary business themes or industries for Elanco Animal Health Inc?
Elanco Animal Health Inc belongs to Pharmaceuticals industry and the sector is Health Care
What is Elanco Animal Health Inc market cap?
Elanco Animal Health Inc's current market cap is $12.5B
Is Elanco Animal Health Inc a buy, sell, or hold?
According to wall street analysts, 15 analysts have made analyst ratings for Elanco Animal Health Inc, including 7 strong buy, 8 buy, 6 hold, 0 sell, and 7 strong sell